| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population |
| Creator | De Laurentiis et al. |
| Author | Michelino De Laurentiis |
| Author | Simona Borstnar |
| Author | Mario Campone |
| Author | Ellen Warner |
| Author | Javier Salvador Bofill |
| Author | William Jacot |
| Author | Susan Dent |
| Author | Miguel Martin |
| Author | Alistair Ring |
| Author | Paul Cottu |
| Author | Janice Lu |
| Author | Eva Ciruelos |
| Author | Hamdy A. Azim |
| Author | Sanjoy Chatterjee |
| Author | Katie Zhou |
| Author | Jiwen Wu |
| Author | Lakshmi Menon-Singh |
| Author | Claudio Zamagni |
| Abstract | PURPOSE: CompLEEment-1 is a phase 3b trial in an expanded patient population with hormone receptor-positive (HR?+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC), the largest current trial of cyclin-dependent kinase 4 and 6 inhibitors in ABC. METHODS: Patients treated with???1 line of prior chemotherapy and no prior endocrine therapy for ABC received ribociclib 600 mg/day (3-weeks-on/1-week-off) plus letrozole 2.5 mg/day and additionally monthly goserelin/leuprolide in men and pre-/perimenopausal women. Eligibility criteria allowed inclusion of patients with stable CNS metastases and an Eastern Cooperative Oncology Group performance status of 2. Primary objectives were safety and tolerability, and secondary objectives were efficacy and quality of life (QoL). RESULTS: Overall, 3,246 patients were evaluated (median follow-up 25.4 months). Rates of all-grade and grade???3 treatment-related adverse events (AEs) were 95.2% and 67.5%, respectively. Treatment-related discontinuations due to all grade and grade???3 AEs occurred in 12.9% and 7.3% of patients, respectively. Rates of all-grade AEs of special interest (AESI) were as follows: neutropenia (74.5%), increased alanine aminotransferase (16.2%), increased aspartate aminotransferase (14.1%), and QTcF prolongation (6.7%); corresponding values for grade???3 AESI were 57.2%, 7.7%, 5.7%, and 1.0%, respectively. Median time to progression was 27.1 months (95% confidence interval, 25.7 to not reached). Patient QoL was maintained during treatment. CONCLUSION: Safety and efficacy data in this expanded population were consistent with the MONALEESA-2 and MONALEESA-7 trials and support the use of ribociclib plus letrozole in the first-line setting for patients with HR?+?, HER2- ABC. TRIAL REGISTRATION: linicalTrials.gov NCT02941926. |
| Publication | Breast Cancer Research and Treatment |
| Volume | 189 |
| Issue | 3 |
| Pages | 689-699 |
| Date | 2021-10 |
| Journal Abbr | Breast Cancer Res Treat |
| Language | eng |
| DOI | 10.1007/s10549-021-06334-0 |
| ISSN | 1573-7217 |
| Library Catalog | PubMed |
| Extra | PMID: 34414532 PMCID: PMC8505291 |
| Tags | Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, CDK4/6 inhibitor, Female, Humans, marque, Purines, Quality of Life, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone, review, Ribociclib |
| Date Added | 2022/07/29 - 12:02:48 |
| Date Modified | 2022/08/01 - 12:34:10 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
